Identifying Signs and Symptoms of Hereditary Transthyretin (hATTR) Amyloidosis in Pharmacy Practice



Suggested Readings

Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy [published online ahead of print, 2020 Jan 6]. *J Neurol.* 2020;10.1007/s00415-019-09688-0. doi:10.1007/s00415-019-09688-0

Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. *N Engl J Med.* 2018;379(1):11-21. doi:10.1056/NEJMoa1716153

Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. *N Engl J Med.* 2018;379(1):22-31. doi:10.1056/NEJMoa1716793

Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. *Amyloid.* 2019;26(1):3-9. doi:10.1080/13506129. 2018.1556156

Gertz MA, Mauermann ML, Grogan M, Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: A review. *Brain Behav.* 2019;9(9):e01371. doi:10.1002/brb3.1371

Kachur, E. Novel therapies for transthyretin amyloidosis. US Pharm. 2019;44(8):8-10. Available: https://www.uspharmacist.com/article/novel-therapies-for-transthyretin-amyloidosis. Accessed October 27, 2020.

Kapoor M, Rossor AM, Laura M, Reilly MM. Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. *J Neuromuscul Dis.* 2019;6(2):189-199. doi:10.3233/JND-180371

Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *N Engl J Med.* 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689

Witteles RM, Bokhari S, Damy T, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. *JACC Heart Fail.* 2019;7(8):709-716. doi:10.1016/j.jchf.2019.04.010

AKH Inc. Advancing Knowledge in Healthcare

Catalyst MEDICAL EDUCATION